Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

Roman Hajek, Jiri Minarik, Stork Martin, Alexandra Jungova, Giselle Lostaunau Costa, Yuwei Wang, Solenn Salaun, Nolen J. Perualila, Guillaume Azarias, Markus Rückert

Blood (2025) 146 (Supplement 1): 4581.

https://doi.org/10.1182/blood-2025-4581

Published: 2025

Journal Articles

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Blood (2025) 146 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2025-1834

Published: 2025

Journal Articles

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

Blood (2025) 146 (Supplement 1): 2803.

https://doi.org/10.1182/blood-2025-2803

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Jiri Minarik, Luděk Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Stork Martin, Jan Straub, Vojtech Latal, Dominik Fric, Vladimir Maisnar, Roman Hajek

Blood (2024) 144 (Supplement 1): 2378.

https://doi.org/10.1182/blood-2024-200014

Published: 2024

Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek

Blood (2024) 144 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2024-202002

Published: 2024

Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek

Blood (2024) 144 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2024-211224

Published: 2024

Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek

Blood (2023) 142 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2023-179299

Published: 2023

Journal Articles

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Roman Hajek, Henrik Sliwka, Martin Stork, Ivan Spicka, Tomas Jelinek, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Jan Soukup, Nolen Joy Perualila, Joris Diels, Michel van Speybroeck, Nichola Erler-Yates, João Mendes, Kai Strobel, Sébastien Wischlen, Maximilian Merz

Blood (2022) 140 (Supplement 1): 7200–7202.

https://doi.org/10.1182/blood-2022-159401

Published: 2022

Journal Articles

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Blood (2021) 138 (Supplement 1): 2716.

https://doi.org/10.1182/blood-2021-148836

Published: 2021

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Blood (2019) 134 (Supplement_1): 3139.

https://doi.org/10.1182/blood-2019-128865

Published: 2019

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Martina Zátopková, MSc, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Jana Filipova, Tomas Jelinek, Lucie Říhová, Renata Bezděková, MSc., Fedor Kryukov, Jana Smejkalová, Jiri Minarik, MD PhD, Vladimir Maisnar, MD, Martin Mistrik, MD PhD, Ludek Pour, MD, Alexandra Jungova, Michal Šimíček, Giovanni Stracquadanio, Roman Hajek

Blood (2018) 132 (Supplement 1): 3175.

https://doi.org/10.1182/blood-2018-99-112611

Published: 2018

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Blood (2018) 132 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2018-99-112046

Published: 2018

Journal Articles

Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients:Â Analysis from Registry of Monoclonal Gammopathies (RMG)

Jakub Radocha, MD, Roman Hajek, Lucie Brozova, MSc, Ludek Pour, MD, Ivan Spicka, MDPhDProf, Jiri Minarik, MD PhD, Evzen Gregora, MD, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, Tomas Pika, Petr Pavlicek, MD, Viera Sandecka, MDPhD, David Vrabel, MSc, Adriana Heindorfer, Martin Stork, MD, Michal Sykora, Vladimir Maisnar, MD

Blood (2018) 132 (Supplement 1): 2019.

https://doi.org/10.1182/blood-2018-99-111882

Published: 2018

Journal Articles

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Blood (2018) 132 (Supplement 1): 5596.

https://doi.org/10.1182/blood-2018-99-114854

Published: 2018

Journal Articles

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Jiri Minarik, MD PhD, Ludek Pour, MD PhD, Vladimir Maisnar, Prof, MD PhD, Ivan Spicka, MDPhD, Alexandra Jungova, MD, Hana Plonkova, Lucie Brozova, MSc, Petra Krhovska, Tomas Pika, Jaroslav Bacovsky, Sabina Sevcikova, RNDr, PhD, Jakub Radocha, MD PhD, Vlastimil Scudla, Prof, MD CSc, Roman Hájek, MD

Blood (2017) 130 (Supplement 1): 5414.

https://doi.org/10.1182/blood.V130.Suppl_1.5414.5414

Published: 2017

Journal Articles

Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

Blood (2016) 128 (22): 3333.

https://doi.org/10.1182/blood.V128.22.3333.3333

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets - Analysis of the Czech Myeloma Group

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients:Â Analysis from Registry of Monoclonal Gammopathies (RMG)

Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma

Single Agent Daratumumab in Advanced Multiple Myeloma: Specific Healthcare Program in the Czech Republic

Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only